Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy and Sandoz, is a world leader in the research and development of products that protect and improve health and well-being.
Its core businesses are pharmaceuticals, vaccines, consumer health, generics, eye care, and animal health.
Novartis derives its name from the Latin words novae artes meaning "new skills." The term reflects the company's commitment to research and development that brings innovative new products to the communities it serves.
In 2006, the Novartis Group Companies achieved net sales of USD 37.0 billion and net income of USD 7.2 billion.
The Group, which invested approximately USD 5.4 billion in research and development (R&D) employs approximately 26,000 people in the US. Globally Novartis employs approximately 101,000 people in more than 140 countries.
Its global headquarters are located in Basel, Switzerland and its US headquarters are in New Jersey.
Leadership
Learn more about the Novartis US leadership team.
Research & Development
At the Novartis Institutes for Biomedical Research (NIBR), the goal is to discover new medicines regularly based on an understanding of molecular mechanisms of disease. NIBR scientists are exploring the intersection of the chemical and biological universes.
History
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis.
